X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Enveda will use the net financing to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Kinnevik
Deal Size: $119.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 20, 2023
Details:
Enveda’s platform is the world’s most advanced drug discovery search engine for dark chemical space, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lux Capital
Deal Size: $51.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
